As genetically modified vectors, combining the tumor-homing capacity of MSCs and genetic engineering of the cells to express tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) will enable the specific targeting of cancer stem cells (CSCs), which would be an attractive cytotherapeutic option for cancer 102. Here, TNFSF10 is linked to cancer.